Rallybio

NEW HAVEN, CT · Founded 2018 · Biotech · Public

Biologics and therapeutic candidates for rare genetic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · rallybio.com

Sector
Biotech
Headquarters
NEW HAVEN, CT
Founded
2018
Latest Form D
$6.6M, Apr 2024
Total capital
$106M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$106M
3 Form D · last Apr 2024
30 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2018201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$6M2nd Form D$93.2M3rd Form D$6.6M
2018202020222024FEDERAL ↑EQUITY ↓Cumulative $106M1st Form D$6M2nd Form D$93.2M3rd Form D$6.6M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$6.6M
  • Private capital raisedForm D · SEC · 2nd filing$93.2M
  • Private capital raisedForm D · SEC · 1st filing$6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • CHRISTINE A. NASHDirectorNamed in SEC Form D filings
  • HELEN M. BOUDREAUDirectorNamed in SEC Form D filings
  • HUI M. LIUDirectorNamed in SEC Form D filings
  • JONATHAN I. LIEBERExecutive OfficerNamed in SEC Form D filings
  • KUSH M. PARMARDirectorNamed in SEC Form D filings
  • LUCIAN M. IANCOVICIDirectorNamed in SEC Form D filings
Show all 12 people
  • MARTIN W. MACKAYDirectorNamed in SEC Form D filings
  • PAULA M. SOTEROPOULOSDirectorNamed in SEC Form D filings
  • ROB K. HOPFNERDirectorNamed in SEC Form D filings
  • RONALD M. HUNTDirectorNamed in SEC Form D filings
  • STEPHEN UDENExecutive Officer, DirectorNamed in SEC Form D filings
  • WENDY K. CHUNGDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Synnovation TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Adicet BioSimilar federal contract value in Biotech · null in contracts
  • REGENXBIO Inc.Similar federal contract value in Biotech · null in contracts
  • Autobahn TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Amicus TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • ReCode TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .